Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BLRX |
---|---|---|
09:32 ET | 6261 | 0.529799 |
09:41 ET | 6800 | 0.5108 |
09:43 ET | 300 | 0.52 |
09:45 ET | 2300 | 0.5107 |
09:48 ET | 1600 | 0.525029 |
09:50 ET | 5600 | 0.5108 |
10:01 ET | 391 | 0.5298 |
10:10 ET | 4100 | 0.5201 |
10:12 ET | 800 | 0.5201 |
10:15 ET | 11491 | 0.5201 |
10:24 ET | 1000 | 0.5453 |
10:28 ET | 500 | 0.5674 |
10:30 ET | 500 | 0.5674 |
10:32 ET | 55084 | 0.53 |
10:33 ET | 56200 | 0.53 |
10:35 ET | 4350 | 0.55 |
10:44 ET | 6515 | 0.55 |
10:48 ET | 300 | 0.5405 |
10:53 ET | 6768 | 0.549 |
10:55 ET | 3464 | 0.531 |
10:57 ET | 180 | 0.531 |
11:00 ET | 500 | 0.5451 |
11:06 ET | 2500 | 0.531 |
11:29 ET | 2430 | 0.54 |
11:42 ET | 100 | 0.532 |
11:56 ET | 600 | 0.531 |
11:58 ET | 100 | 0.545 |
12:02 ET | 800 | 0.5348 |
12:05 ET | 2806 | 0.545 |
12:09 ET | 400 | 0.5449 |
12:14 ET | 180 | 0.5385 |
12:21 ET | 8986 | 0.545 |
12:34 ET | 700 | 0.5549 |
12:38 ET | 196 | 0.550101 |
12:41 ET | 2762 | 0.55 |
12:50 ET | 500 | 0.532 |
01:32 ET | 1000 | 0.5448 |
01:35 ET | 100 | 0.54 |
01:42 ET | 100 | 0.54 |
02:00 ET | 1500 | 0.54 |
02:09 ET | 336 | 0.5447 |
02:13 ET | 250 | 0.5401 |
02:15 ET | 5800 | 0.5494 |
02:31 ET | 72329 | 0.54 |
02:38 ET | 9625 | 0.5501 |
02:40 ET | 999 | 0.5501 |
02:42 ET | 1100 | 0.5598 |
02:45 ET | 100 | 0.5501 |
02:54 ET | 16873 | 0.545 |
02:56 ET | 400 | 0.5549 |
03:02 ET | 400 | 0.5549 |
03:03 ET | 22100 | 0.564 |
03:07 ET | 5433 | 0.5575 |
03:09 ET | 11509 | 0.5501 |
03:14 ET | 2000 | 0.5556 |
03:25 ET | 100 | 0.5555 |
03:39 ET | 2897 | 0.542 |
03:57 ET | 100 | 0.5421 |
03:59 ET | 2075 | 0.5466 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
BioLine RX Ltd | 48.2M | -0.7x | --- |
Cue Biopharma Inc | 46.7M | -0.9x | --- |
Marker Therapeutics Inc | 44.3M | -3.6x | --- |
LAVA Therapeutics NV | 49.7M | -1.8x | --- |
Dyadic International Inc | 42.1M | -5.3x | --- |
Palatin Technologies Inc | 29.0M | -0.8x | --- |
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $48.2M |
---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.52 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 4.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.